Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

PD-L1 rs2297136

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

PD-L1 elevation (15)

TMB-H + PD-L1 expression (15)

EGFR mutation + PD-L1 overexpression (8)

TMB-H + PD-L1 overexpression (7)

EGFR exon 19 deletion + PD-L1 overexpression (5)

EGFR mutation + PD-L1 expression (5)

KRAS G12C + PD-L1 overexpression (4)

KRAS mutation + PD-L1 expression (4)

MSI-H/dMMR + PD-L1 expression (4)

PD-L1 expression + EGFR mutation (4)

CD74-ROS1 F2004L + PD-L1 expression (3)

EGFR wild-type + ALK wild-type + PD-L1 expression (3)

MSI-H/dMMR + TMB-H + PD-L1 negative (3)

PD-L1 expression + TMB-H (3)

PD-L1 overexpression + KRAS mutation (3)

ALK rearrangement + PD-L1 overepxression (2)

BRAF V600E + PD-L1 expression (2)

BRAF V600E + PD-L1 expression (2)

EGFR L858R + PD-L1 overexpression (2)

EGFR exon 19 deletion + PD-L1 expression (2)

HER-2 amplification + PD-L1 expression (2)

KRAS G12C + PD-L1 underexpression (2)

KRAS mutation + PD-L1 negative (2)

MSI-H/dMMR + TMB-H + PD-L1 overexpression (2)

PD-1-L + PD-L1 elevation (2)

PD-L1 expression + NRAS Q61R + BRAF D594N (2)

PD-L1 expression + TMB-H + FANCA deletion (2)

PD-L1 overexpression + BRAF V600E (2)

PD-L1 overexpression + EGFR mutation (2)

PD-L1 overexpression + FGFR3 amplification (2)

PD-L1 overexpression + MET exon 14 mutation (2)

RAD51B promoter methylation + PD-L1 expression (2)

TMB-H + PD-L1 negative (2)

TMB-H + PD-L1 underexpression (2)

TMB-L + PD-L1 expression (2)

ALK wild-type + NT5E overexpression + PD-L1 expression (1)

ALK-EML4_V3a + PD-L1 overexpression (1)

ALK-EML4_V3b + PD-L1 overexpression (1)

BAP1 R300Gfs*6 + PD-L1 expression (1)

BAP1 deletion + TMB-L + PD-L1 expression (1)

BRAF E501Q + PD-L1 negative (1)

BRAF V600 + LDH elevation + PD-L1 negative (1)

BRAF mutation + PD-L1 overexpression (1)

BRCA1 mutation + PD-L1 expression (1)

CDKN2A mutation + PD-L1 overexpression (1)

Chr del(9p) + PD-L1 overexpression (1)

DDR + PD-L1 expression (1)

EGFR G719A + EGFR S768I + PD-L1 overexpression (1)

EGFR G719A + PD-L1 overexpression (1)

EGFR L747P + PD-L1 overexpression (1)

EGFR L858R + PD-L1 expression (1)

EGFR L858R + PD-L1 underexpression (1)

EGFR P719A + PD-L1 overexpression (1)

EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression (1)

EGFR exon 19 deletion + EGFR T790M + PD-L1 expression (1)

EGFR exon 19 deletion + PD-L1 underexpression (1)

EGFR exon 20 insertion + PD-L1 overexpression (1)

EGFR fusion + PD-L1 overexpression (1)

EGFR mutation + PD-L1 elevation (1)

EGFR mutation + PD-L1 expression + TP53 mutation (1)

EGFR mutation + PD-L1 negative (1)

EGFR negative + ALK negative + PD-L1 expression (1)

EGFR wild-type + ALK wild-type + NT5E overexpression + PD-L1 expression (1)

FGFR mutation + PD-L1 expression (1)

HER-2 exon 20 insertion + TMB-L + PD-L1 negative (1)

HLA-A*02 + PD-L1 expression (1)

HLA-A*02:01 + PD-L1 expression (1)

HRAS Q61R + TP53 P278S + PD-L1 overexpression (1)

KEAP1 mutation + TMB-H + PD-L1 overexpression (1)

KMT2C mutation + BCOR mutation + KDM5C mutation + PD-L1 expression (1)

KRAS G12C + PD-L1 expression (1)

KRAS G12C + PD-L1 underexpression + STK11 mutation (1)

KRAS mutation + PTPN11 overexpression + PD-L1 overexpression (1)

KRAS mutation + PD-L1 underexpression (1)

KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression (1)

LDHA-L + PD-L1 expression (1)

LDHB-L + PD-L1 expression (1)

MET exon 14 mutation + MET amplification + PD-L1 overexpression (1)

MGAM mutation + PD-L1 overexpression (1)

PAPPA2 mutation + PD-L1 expression (1)

PD-L1 amplification + CD3D overexpression (1)

PD-L1 amplification + HLA-DRA overexpression (1)

PD-L1 amplification + LAG3 overexpression (1)

PD-L1 amplification + PD-L2 amplification + TMB-H (1)

PD-L1 deletion + STK11 mutation (1)

PD-L1 elevation + CXCL10 elevation + TNFA elevation (1)

PD-L1 expression + BRAF negative (1)

PD-L1 expression + JAK2 mutation (1)

PD-L1 expression + KMT2D mutation (1)

PD-L1 expression + MSI-H/dMMR (1)

PD-L1 expression + MSI-L/dMMR (1)

PD-L1 expression + PIK3CA mutation (1)

PD-L1 expression + STK11 mutation (1)

PD-L1 expression + STK11 mutation + JAK2 mutation (1)

PD-L1 expression + T-cell gene signature (1)

PD-L1 negative + KRAS G12C (1)

PD-L1 negative + TMB-L (1)

PD-L1 negative + TMB-L + STING overexpression (1)

PD-L1 overexpression + HER-2 exon 20 insertion (1)

PD-L1 overexpression + KRAS G12C + TP53 mutation (1)

PD-L1 overexpression + RET-CCDC6 fusion (1)

PD-L1 overexpression + RET-KIF5B fusion (1)

PD-L1 overexpression + RET-KIF5B fusion + TP53 mutation + AR mutation + RET rearrangement (1)

PD-L1 overexpression + TMB-H (1)

PD-L1 overexpression + TMB-H + ARID1A F2141fs*59 (1)

PD-L1 overexpression + TMB-L (1)

PD-L1 underexpression + EGFR mutation (1)

PIK3CA R88Q + PD-L1 expression (1)

POLE mutation + PD-L1 negative + TMB-H (1)

RB1 mutation + PD-L1 expression (1)

RET amplification + TMB-H + PD-L1 expression (1)

ROS1 rearrangement + PD-L1 overexpression (1)

RYR1 mutation + PD-L1 overexpression (1)

SMARCA4 deletion + dMMR/MSI-H + PD-L1 underexpression (1)

SQSTM1-NTRK1 + PIK3CA E545K + TP53 L145R + PD-L1 overexpression (1)

STK11 mutation + TMB-H + PD-L1 overexpression (1)

TERT positive + PD-L1 expression (1)

TMB-H + PD-L1 expression + MSI-L/dMMR (1)

TMB-H + RB1 mutation + PD-L1 underexpression (1)

TMB-L + PD-L1 underexpression (1)

TP53 mutation + MET amplification + PD-L1 overexpression (1)

TP53 mutation + PD-L1 expression (1)

TP53 mutation + PD-L1 negative (1)

TP53 mutation + TMB-H + PD-L1 overexpression (1)

TTF1 expression + NAPSA expression + PD-L1 expression + TMB-H (1)

ARID1A mutation + PD-L1 expression (0)

DDX3X mutation + PD-L1 overexpression (0)

LDHA-H + PD-L1 negative (0)

LDHB-H + PD-L1 negative (0)

NOTCH4 mutation + PD-L1 expression + TMB-H (0)

PD-L1 overexpression + BRAF mutation (0)

PD-L1 underexpression + ALK wild-type (0)

PD-L1 underexpression + EGFR wild-type (0)

STAT3 mutation + PD-L1 overexpression (0)

PD-L1 elevation (15)

TMB-H + PD-L1 expression (15)

EGFR mutation + PD-L1 overexpression (8)

TMB-H + PD-L1 overexpression (7)

EGFR exon 19 deletion + PD-L1 overexpression (5)

EGFR mutation + PD-L1 expression (5)

KRAS G12C + PD-L1 overexpression (4)

KRAS mutation + PD-L1 expression (4)

MSI-H/dMMR + PD-L1 expression (4)

PD-L1 expression + EGFR mutation (4)

CD74-ROS1 F2004L + PD-L1 expression (3)

EGFR wild-type + ALK wild-type + PD-L1 expression (3)

MSI-H/dMMR + TMB-H + PD-L1 negative (3)

PD-L1 expression + TMB-H (3)

PD-L1 overexpression + KRAS mutation (3)

ALK rearrangement + PD-L1 overepxression (2)

BRAF V600E + PD-L1 expression (2)

BRAF V600E + PD-L1 expression (2)

EGFR L858R + PD-L1 overexpression (2)

EGFR exon 19 deletion + PD-L1 expression (2)

HER-2 amplification + PD-L1 expression (2)

KRAS G12C + PD-L1 underexpression (2)

KRAS mutation + PD-L1 negative (2)

MSI-H/dMMR + TMB-H + PD-L1 overexpression (2)

PD-1-L + PD-L1 elevation (2)

PD-L1 expression + NRAS Q61R + BRAF D594N (2)

PD-L1 expression + TMB-H + FANCA deletion (2)

PD-L1 overexpression + BRAF V600E (2)

PD-L1 overexpression + EGFR mutation (2)

PD-L1 overexpression + FGFR3 amplification (2)

PD-L1 overexpression + MET exon 14 mutation (2)

RAD51B promoter methylation + PD-L1 expression (2)

TMB-H + PD-L1 negative (2)

TMB-H + PD-L1 underexpression (2)

TMB-L + PD-L1 expression (2)

ALK wild-type + NT5E overexpression + PD-L1 expression (1)

ALK-EML4_V3a + PD-L1 overexpression (1)

ALK-EML4_V3b + PD-L1 overexpression (1)

BAP1 R300Gfs*6 + PD-L1 expression (1)

BAP1 deletion + TMB-L + PD-L1 expression (1)

BRAF E501Q + PD-L1 negative (1)

BRAF V600 + LDH elevation + PD-L1 negative (1)

BRAF mutation + PD-L1 overexpression (1)

BRCA1 mutation + PD-L1 expression (1)

CDKN2A mutation + PD-L1 overexpression (1)

Chr del(9p) + PD-L1 overexpression (1)

DDR + PD-L1 expression (1)

EGFR G719A + EGFR S768I + PD-L1 overexpression (1)

EGFR G719A + PD-L1 overexpression (1)

EGFR L747P + PD-L1 overexpression (1)

EGFR L858R + PD-L1 expression (1)

EGFR L858R + PD-L1 underexpression (1)

EGFR P719A + PD-L1 overexpression (1)

EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression (1)

EGFR exon 19 deletion + EGFR T790M + PD-L1 expression (1)

EGFR exon 19 deletion + PD-L1 underexpression (1)

EGFR exon 20 insertion + PD-L1 overexpression (1)

EGFR fusion + PD-L1 overexpression (1)

EGFR mutation + PD-L1 elevation (1)

EGFR mutation + PD-L1 expression + TP53 mutation (1)

EGFR mutation + PD-L1 negative (1)

EGFR negative + ALK negative + PD-L1 expression (1)

EGFR wild-type + ALK wild-type + NT5E overexpression + PD-L1 expression (1)

FGFR mutation + PD-L1 expression (1)

HER-2 exon 20 insertion + TMB-L + PD-L1 negative (1)

HLA-A*02 + PD-L1 expression (1)

HLA-A*02:01 + PD-L1 expression (1)

HRAS Q61R + TP53 P278S + PD-L1 overexpression (1)

KEAP1 mutation + TMB-H + PD-L1 overexpression (1)

KMT2C mutation + BCOR mutation + KDM5C mutation + PD-L1 expression (1)

KRAS G12C + PD-L1 expression (1)

KRAS G12C + PD-L1 underexpression + STK11 mutation (1)

KRAS mutation + PTPN11 overexpression + PD-L1 overexpression (1)

KRAS mutation + PD-L1 underexpression (1)

KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression (1)

LDHA-L + PD-L1 expression (1)

LDHB-L + PD-L1 expression (1)

MET exon 14 mutation + MET amplification + PD-L1 overexpression (1)

MGAM mutation + PD-L1 overexpression (1)

PAPPA2 mutation + PD-L1 expression (1)

PD-L1 amplification + CD3D overexpression (1)

PD-L1 amplification + HLA-DRA overexpression (1)

PD-L1 amplification + LAG3 overexpression (1)

PD-L1 amplification + PD-L2 amplification + TMB-H (1)

PD-L1 deletion + STK11 mutation (1)

PD-L1 elevation + CXCL10 elevation + TNFA elevation (1)

PD-L1 expression + BRAF negative (1)

PD-L1 expression + JAK2 mutation (1)

PD-L1 expression + KMT2D mutation (1)

PD-L1 expression + MSI-H/dMMR (1)

PD-L1 expression + MSI-L/dMMR (1)

PD-L1 expression + PIK3CA mutation (1)

PD-L1 expression + STK11 mutation (1)

PD-L1 expression + STK11 mutation + JAK2 mutation (1)

PD-L1 expression + T-cell gene signature (1)

PD-L1 negative + KRAS G12C (1)

PD-L1 negative + TMB-L (1)

PD-L1 negative + TMB-L + STING overexpression (1)

PD-L1 overexpression + HER-2 exon 20 insertion (1)

PD-L1 overexpression + KRAS G12C + TP53 mutation (1)

PD-L1 overexpression + RET-CCDC6 fusion (1)

PD-L1 overexpression + RET-KIF5B fusion (1)

PD-L1 overexpression + RET-KIF5B fusion + TP53 mutation + AR mutation + RET rearrangement (1)

PD-L1 overexpression + TMB-H (1)

PD-L1 overexpression + TMB-H + ARID1A F2141fs*59 (1)

PD-L1 overexpression + TMB-L (1)

PD-L1 underexpression + EGFR mutation (1)

PIK3CA R88Q + PD-L1 expression (1)

POLE mutation + PD-L1 negative + TMB-H (1)

RB1 mutation + PD-L1 expression (1)

RET amplification + TMB-H + PD-L1 expression (1)

ROS1 rearrangement + PD-L1 overexpression (1)

RYR1 mutation + PD-L1 overexpression (1)

SMARCA4 deletion + dMMR/MSI-H + PD-L1 underexpression (1)

SQSTM1-NTRK1 + PIK3CA E545K + TP53 L145R + PD-L1 overexpression (1)

STK11 mutation + TMB-H + PD-L1 overexpression (1)

TERT positive + PD-L1 expression (1)

TMB-H + PD-L1 expression + MSI-L/dMMR (1)

TMB-H + RB1 mutation + PD-L1 underexpression (1)

TMB-L + PD-L1 underexpression (1)

TP53 mutation + MET amplification + PD-L1 overexpression (1)

TP53 mutation + PD-L1 expression (1)

TP53 mutation + PD-L1 negative (1)

TP53 mutation + TMB-H + PD-L1 overexpression (1)

TTF1 expression + NAPSA expression + PD-L1 expression + TMB-H (1)

ARID1A mutation + PD-L1 expression (0)

DDX3X mutation + PD-L1 overexpression (0)

LDHA-H + PD-L1 negative (0)

LDHB-H + PD-L1 negative (0)

NOTCH4 mutation + PD-L1 expression + TMB-H (0)

PD-L1 overexpression + BRAF mutation (0)

PD-L1 underexpression + ALK wild-type (0)

PD-L1 underexpression + EGFR wild-type (0)

STAT3 mutation + PD-L1 overexpression (0)

›

9ms

Associations of PD-1 and PD-L1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies. (PubMed, Aging (Albany NY))

The rs7421861 polymrophism decreased cancer risk among Caucasians, rather than the rs10815225 elevated cancer risk. Our results supported that PD-1 and PD-L1 SNPs were dramatically correlated with cancer risk.

9 months ago

Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker

|

PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)

|

PD-L1 rs2297136 • PD-L1 rs4143815

10ms

Implication of PD‑L1 polymorphisms rs2297136 on clinical outcomes of patients with advanced NSCLC who received PD‑1 blockades: A retrospective exploratory study. (PubMed, Oncol Lett)

In clinical practice, PD-1 blockades demonstrated promising effectiveness in treating patients with advanced NSCLC. The presence of the rs2297136 variant in PD-L1 gene could potentially be used as a biomarker to predict the clinical outcomes of PD-1 blockades.

10 months ago

Clinical data • Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases

|

PD-L1 (Programmed death ligand 1)

|

PD-L1 expression • PD-L1 rs2297136

11ms

The predictive and prognostic role of single nucleotide gene variants of PD-1 and PD-L1 in patients with advanced melanoma treated with PD-1 inhibitors. (PubMed, Immunooncol Technol)

We analysed, in metastatic melanoma patients treated with nivolumab or pembrolizumab, five PD-1 SNVs, namely PD1.3 G>A (rs11568821), PD1.5 C>T (rs2227981), PD1.6 G>A (rs10204525), PD1.7 T>C(rs7421861), PD1.10 C>G (rs5582977) and three programmed death-ligand 1 (PD-L1) SNVs: +8293 C>A (rs2890658), PD-L1 C>T (rs2297136) and PD-L1 G>C (rs4143815). Our study showed that PD-1.5 and PD-L1 +8293 SNVs may play a role as a predictive biomarker of development of irAEs to PD-1 inhibitors. PD1.7 SNV may also be associated with a reduction of the risk of death, although further translational research is needed to confirm these results.

11 months ago

Journal • PD(L)-1 Biomarker • IO biomarker • Metastases

|

PD-L1 (Programmed death ligand 1)

|

PD-L1 rs2297136 • PD-L1 rs4143815

|

Keytruda (pembrolizumab) • Opdivo (nivolumab)